Bench
Library

AOD-9604

Metabolic

Also known as hGH fragment 176-191

Growth hormone fragment marketed for fat loss. Failed its phase 2b trial.

Read this first
This compound has no published pharmacokinetics, no identified receptor, and a failed phase 2b trial. Any claim that it produces meaningful fat loss is contradicted by its own trial result.

How it works

A synthetic fragment of the C-terminal region of human growth hormone. A lipolytic effect independent of the growth hormone receptor is claimed, but no receptor target has ever been identified and no mechanism is established.

SubcutaneousOral

In the body

No plasma curve is shown for this compound.

No human pharmacokinetic data has ever been published. There are zero registered trials on ClinicalTrials.gov and no PubMed pharmacokinetic results. No curve can honestly be drawn.

Doses

300 mcg, 1 mgonce dailyCommunity practice

Community protocols only. The phase 2b trial is described as using around 1 mg daily but the dose could not be verified from any primary source.

Side effects

  • No systematic safety data exists.

Cautions

  • Development was discontinued. The phase 2b trial did not show significant weight loss against placebo.
  • Prohibited by WADA as a growth hormone fragment.

Status

Never approved. The FDA declined to place it on the 503A bulk substances list for compounding. Its own trial did not meet its endpoint.

Sources

Reference information for personal record-keeping. Not medical advice, and not a recommendation to use any of these compounds.